See the original post here:
Olympia Pharmaceuticals Announces the Launch of Sister Brand, Wesley Pharmaceuticals, in Honor of Beloved Employee
Related Post
- ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal... - December 19th, 2024
- Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies - December 19th, 2024
- Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - December 19th, 2024
- Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor - December 19th, 2024
- Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - December 19th, 2024
- Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology - December 19th, 2024
- Akari Therapeutics Announces Key Leadership Appointments - December 19th, 2024
- The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is... - December 19th, 2024
- Rafarma pharmaceutical updates - December 19th, 2024
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor - December 19th, 2024
- BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions - December 19th, 2024
- Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics - December 19th, 2024
- Longeveron to Present at Biotech Showcase 2025 - December 19th, 2024
- TigaTx Announces up to $35.5M in Funding from ARPA-H and NIH Awards to Advance First-in-Class Engineered IgA Monoclonal Antibody for Cancer and... - December 19th, 2024
- OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO - December 19th, 2024
- Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction - December 19th, 2024
- Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment - December 19th, 2024
- Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - December 19th, 2024
- Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - December 19th, 2024
- Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - December 17th, 2024
- Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference - December 17th, 2024
- Upstream Bio Announces Addition to Russell 2000® Index - December 17th, 2024
- FibroGen Appoints David DeLucia as Chief Financial Officer - December 17th, 2024
- Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 17th, 2024
- Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - December 17th, 2024
- Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 17th, 2024
- Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - December 17th, 2024
- Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in... - December 17th, 2024
- New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 - December 17th, 2024
- invIOs to present progress across oncology pipeline during JP Morgan Week 2025 - December 17th, 2024
- Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - December 17th, 2024
- Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - December 17th, 2024
- Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike - December 17th, 2024
- Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis - December 17th, 2024
- Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update - December 17th, 2024
- Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation - December 17th, 2024
- Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic... - December 17th, 2024
- Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - December 17th, 2024
- Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - December 17th, 2024
- Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular... - December 15th, 2024
- HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - December 15th, 2024
- LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - December 15th, 2024
- Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - December 15th, 2024
- Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement - December 15th, 2024
- Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - December 15th, 2024
- Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo... - December 15th, 2024
- Pharming announces public cash offer to the shareholders of Abliva AB - December 15th, 2024
- Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis - December 13th, 2024
- Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities - December 13th, 2024
- Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and... - December 13th, 2024
- Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness - December 13th, 2024
- ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 13th, 2024
- Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - December 13th, 2024
- Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance - December 13th, 2024
- Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - December 13th, 2024
- Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast... - December 13th, 2024
- Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - December 13th, 2024
- Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - December 13th, 2024
- Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast... - December 13th, 2024
- Amarin Appoints Peter Fishman Chief Financial Officer - December 13th, 2024
- SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - December 13th, 2024
- Spectral AI Comments on Compliance with Nasdaq Listing Rule 5550(b)(2) - December 13th, 2024
- Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - December 13th, 2024
- UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - December 13th, 2024
- CannExpo 2025: Igniting the Cannabis Lifestyle in Toronto - December 13th, 2024
- Outlook Therapeutics® Streamlines Operations - December 13th, 2024
- Edesa Biotech Reports Fiscal Year 2024 Results - December 13th, 2024
- Kraig Biocraft Laboratories Reports Record-Setting Recombinant Spider Silk Production in 2024 - December 11th, 2024
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - December 11th, 2024
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in... - December 11th, 2024
- AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed - December 11th, 2024
- Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient... - December 11th, 2024
- Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting - December 11th, 2024
- RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic... - December 11th, 2024
- Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy - December 11th, 2024
- Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients - December 11th, 2024
- Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - December 11th, 2024
- Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - December 11th, 2024
- Angitia Biopharmaceuticals Announces $120 Million Series C Financing - December 11th, 2024
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - December 11th, 2024
Recent Comments